Laboratory of Technology and Pharmaceutical Biotechnology (Tecbiofar), Department of Pharmaceutical Sciences, College of Pharmacy, Federal University of Rio Grande do Norte (UFRN), Rua General Gustavo Cordeiro de Farias, S/N, Petrópolis, Natal 59012-570, Brazil.
Laboratory of Computational Chemistry, Chemistry Institute, Federal University of Rio Grande do Norte (UFRN), Av. Senador Salgado Filho, 3000, Lagoa Nova, Natal 59072-970, Brazil.
Pharmacol Res. 2022 Jul;181:106245. doi: 10.1016/j.phrs.2022.106245. Epub 2022 May 5.
Multidrug-resistant bacterial infections are a threat to public health worldwide, which boosts the urgent need for pharmacological research for new drugs. Although the peptides without disulfide bridges from scorpions have shown antimicrobial action, usually their toxicity hamper their pharmacological application. Stigmurin is a non-hemolytic cationic peptide from Tityus stigmurus venom with antibacterial effect and toxicity on normal cells. In this approach, the conformational changes and stability of two Stigmurin analog peptides, named StigA8 and StigA18, were evaluated by circular dichroism, as well as the mechanism of interaction with bacterial membranes in silico. In addition, the in vitro and in vivo antibacterial activity and the action against the biofilm formed by multidrug-resistant Staphylococcus aureus were investigated. StigA8 (+4) and StigA18 (+5) revealed the ability to change their structural conformation depending on the medium composition, and high stability at different temperatures and pH conditions. Both analog peptides showed greater ability to interact with bacterial membranes in silico when compared to the native one. StigA8 and StigA18 demonstrated low hemolytic action, with non-toxic effect on G. mellonella larvae up to 120 mg/kg. StigA8 and StigA18 presented a broad spectrum of antibacterial action in vitro, especially against multidrug-resistant clinical isolates. The analog peptides (7.5 µM) also reduced the biofilm biomass of multidrug-resistant S. aureus, as well as increased the larval survival of the Galleria mellonella infected larvae. Therefore, StigA8 and StigA18 showed a beneficial potential in the treatment of bacterial infections, constituting promising bioactive components for the development of new antimicrobial agents.
多药耐药菌感染对全球公共卫生构成威胁,这促使人们迫切需要开展药理学研究以开发新的药物。尽管来自蝎子的无二硫键肽已显示出抗菌作用,但通常它们的毒性会阻碍其药理学应用。Stigmurin 是一种来自 Tityus stigmurus 毒液的非溶血阳离子肽,具有抗菌作用和对正常细胞的毒性。在本研究中,通过圆二色性评估了两种 Stigmurin 类似肽(命名为 StigA8 和 StigA18)的构象变化和稳定性,并通过计算机模拟研究了它们与细菌膜相互作用的机制。此外,还研究了这两种类似肽的体外和体内抗菌活性以及对耐多药金黄色葡萄球菌生物膜的作用。StigA8(+4)和 StigA18(+5)表现出根据介质组成改变其结构构象的能力,并且在不同温度和 pH 条件下具有高稳定性。与天然肽相比,这两种类似肽在计算机模拟中表现出与细菌膜更强的相互作用能力。StigA8 和 StigA18 表现出较低的溶血作用,对 G. mellonella 幼虫的毒性作用在 120mg/kg 以下。StigA8 和 StigA18 在体外表现出广谱的抗菌作用,特别是对耐多药临床分离株。类似肽(7.5µM)还降低了耐多药金黄色葡萄球菌生物膜的生物量,并增加了感染幼虫的 G. mellonella 幼虫的存活率。因此,StigA8 和 StigA18 在治疗细菌感染方面显示出有益的潜力,为开发新的抗菌药物提供了有前景的生物活性成分。